Associated Papers
SLC18A2 associated infantile-onset- parkinsonism-dystonia 2: A novel genotype.
Janardhanan A et al.
Parkinsonism & Related Disorders, 2025
Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants.
Wang X et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 2024
39060436 (PubMed )
Supplement: 41386_2024_1914_MOESM1_ESM.docx
Structural mechanisms for VMAT2 inhibition by tetrabenazine.
Dalton MP et al.
Elife, 2024
Structural mechanisms for VMAT2 inhibition by tetrabenazine.
Dalton MP et al.
Biorxiv : the Preprint Server for Biology, 2024
Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.
Pidathala S et al.
Nature, 2023
Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits.
Bhat S et al.
Pharmacology & Therapeutics, 2021
A novel missense variant in SLC18A2 causes recessive brain monoamine vesicular transport disease and absent serotonin in platelets.
Padmakumar M et al.
Jimd Reports, 2019
Select a paper to view details